Search Results for "empagliflozin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for empagliflozin. Results 11 to 20 of 20 total matches.
See also: Jardiance

Bexagliflozin (Brenzavvy) — A Fifth SGLT2 Inhibitor for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023  (Issue 1683)
(Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) are FDA-approved to improve cardiac ...
Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the FDA to improve glycemic control in adults with type 2 diabetes. It is the fifth SGLT2 inhibitor to be approved in the US for this indication (see Table 4).
Med Lett Drugs Ther. 2023 Aug 21;65(1683):130-2   doi:10.58347/tml.2023.1683b |  Show IntroductionHide Introduction

Drugs for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
was superior to addition of the SGLT2 inhibitor empagliflozin or the DPP-4 inhibitor sitagliptin ...
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-84 |  Show IntroductionHide Introduction

A Renal Indication for Semaglutide (Ozempic)

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025  (Issue 1723)
), and empagliflozin (Jardiance), which were initially approved for treatment of type 2 diabetes, have also ...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk) has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD). It is the first GLP-1 receptor agonist to be approved in the US for this indication.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):38-40   doi:10.58347/tml.2025.1723d |  Show IntroductionHide Introduction

Vericiguat (Verquvo) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
., dapagliflozin, empagliflozin) should be added in patients who do not have severe renal impairment.2-5 In black ...
The FDA has approved vericiguat (Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a worsening heart failure event (hospitalization for heart failure or treatment with IV diuretics as an outpatient) in patients with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) <45%. Vericiguat is the second sGC stimulator to be marketed in the US. Riociguat (Adempas), which is FDA-approved for treatment of pulmonary arterial hypertension...
Med Lett Drugs Ther. 2021 Mar 8;63(1619):36-7 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for HFrEF (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
) inhibitor (i.e., dapagliflozin, empagliflozin) should be added in patients who do not have severe renal ...
View the Comparison Table: Some Drugs for HFrEF
Med Lett Drugs Ther. 2021 Mar 8;63(1619):e1-14 |  Show IntroductionHide Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jun 14, 2021  (Issue 1626)
/day8 10 mg once/day 532.80 Empagliflozin – Jardiance 10, 25 mg tabs 10 mg once/day9 10 mg once/day ...
Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Those with a LVEF of 41-49% are an intermediate group more similar to patients with HFpEF.
Med Lett Drugs Ther. 2021 Jun 14;63(1626):89-96 |  Show IntroductionHide Introduction

In Brief: Canagliflozin and Lower Limb Amputations

   
The Medical Letter on Drugs and Therapeutics • Sep 21, 2020  (Issue 1607)
. The SGLT2 inhibitors dapagliflozin (Farxiga) and empagliflozin (Jardiance) have not been associated ...
The FDA has removed a boxed warning from the labeling of products containing the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin (Invokana, Invokamet, Invokamet XR) that described an increased risk of lower limb amputation associated with use of the drug. Package inserts for canagliflozin products still contain a standard warning about a risk of lower limb amputation.
Med Lett Drugs Ther. 2020 Sep 21;62(1607):152 |  Show IntroductionHide Introduction

Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
with empagliflozin/ linagliptin (Glyxambi).7 Missed Dose Instructions for GLP-1 and GIP/GLP-1 Agonists for Type 2 ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-3   doi:10.58347/tml.2024.1708c |  Show IntroductionHide Introduction

In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
, or empagliflozin) should be added in patients with an eGFR ≥20 mL/min/1.73 m2 and albuminuria5 Addition ...
Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to standard treatment in patients with type 2 diabetes and chronic kidney disease (CKD).
Med Lett Drugs Ther. 2023 Jan 23;65(1668):15-6   doi:10.58347/tml.2023.1668e |  Show IntroductionHide Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
., empagliflozin), and caffeine, can decrease lithium concentrations.2,3 Valproate Moderate inhibitor of CYP2C9 ...
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54   doi:10.58347/tml.2024.1699a |  Show IntroductionHide Introduction